Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (201-210 of 436) with videos related to

Pageof 44
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancerAnn H Partridge, Philip S Wang, Eric P Winer, et al.
Journal of the National Cancer Institute|May 2, 2002
Adherence to therapy with oral antineoplastic agentsAnn H Partridge, Jerry Avorn, Philip S Wang, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 6, 2020
Origins and Ownership of Remdesivir: Implications for PricingChangWon C Lee, Jonathan J Darrow, Jerry Avorn, et al.
Drug Discovery Today|October 4, 2020
Public funding for transformative drugs: the case of sofosbuvirRachel E Barenie, Jerry Avorn, Frazer A Tessema, et al.
JAMA Internal Medicine|July 19, 2021
Public-sector Contributions to Novel Biologic DrugsRahul K Nayak, ChangWon C Lee, Jerry Avorn, et al.
The New England Journal of Medicine|January 13, 2021
The Future of Drug-Pricing TransparencyWilliam B Feldman, Benjamin N Rome, Jerry Avorn, et al.
Circulation. Cardiovascular Quality and Outcomes|June 15, 2017
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein InhibitorsSpencer Phillips Hey, Jessica M Franklin, Jerry Avorn, et al.
American Heart Journal|December 28, 2020
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort studyBenjamin N Rome, Joshua J Gagne, Jerry Avorn, et al.
JAMA Internal Medicine|August 6, 2019
Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor BlockersMatthew E Growdon, Chana A Sacks, Aaron S Kesselheim, et al.
BMJ (Clinical Research Ed.)|February 26, 2004
Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluationsSebastian Schneeweiss, Malcolm Maclure, Bruce Carleton, et al.
Pageof 44

Showing results (201-210 of 436) with videos related to

Sort By:
Pageof 44
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancerAnn H Partridge, Philip S Wang, Eric P Winer, et al.
Journal of the National Cancer Institute|May 2, 2002
Adherence to therapy with oral antineoplastic agentsAnn H Partridge, Jerry Avorn, Philip S Wang, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 6, 2020
Origins and Ownership of Remdesivir: Implications for PricingChangWon C Lee, Jonathan J Darrow, Jerry Avorn, et al.
Drug Discovery Today|October 4, 2020
Public funding for transformative drugs: the case of sofosbuvirRachel E Barenie, Jerry Avorn, Frazer A Tessema, et al.
JAMA Internal Medicine|July 19, 2021
Public-sector Contributions to Novel Biologic DrugsRahul K Nayak, ChangWon C Lee, Jerry Avorn, et al.
The New England Journal of Medicine|January 13, 2021
The Future of Drug-Pricing TransparencyWilliam B Feldman, Benjamin N Rome, Jerry Avorn, et al.
Circulation. Cardiovascular Quality and Outcomes|June 15, 2017
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein InhibitorsSpencer Phillips Hey, Jessica M Franklin, Jerry Avorn, et al.
American Heart Journal|December 28, 2020
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort studyBenjamin N Rome, Joshua J Gagne, Jerry Avorn, et al.
JAMA Internal Medicine|August 6, 2019
Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor BlockersMatthew E Growdon, Chana A Sacks, Aaron S Kesselheim, et al.
BMJ (Clinical Research Ed.)|February 26, 2004
Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluationsSebastian Schneeweiss, Malcolm Maclure, Bruce Carleton, et al.
Pageof 44